Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.
Nicolas Girard, MD
Advertisement
Nicolas Girard, MD, is professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon.
Articles by Nicolas Girard, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Fall 2025 Quiz: Test Your Pharmacy Knowledge!
2
Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health
3
FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms
4
Menopause Care Varies by Provider, Highlighting Need for Standardized Education
5
